FDAnews
www.fdanews.com/articles/126337-mylan-announces-approval-under-pepfar-for-generic-videx-ec-hiv-treatment

Mylan Announces Approval Under PEPFAR for Generic Videx EC HIV Treatment

April 19, 2010
Mylan Inc. Monday announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb’s HIV treatment Videx EC.
Centre Daily Times